High frequency of allelic loss at the BRCA1 locus in ovarian cancers: Clinicopathologic and molecular associations

Cancer Genetics

Volumn 205, Issue 3, 2012, Pages 94-100

  Rzepecka, Iwona K ^a   Szafron, Lukasz ^a   Stys, Agnieszka ^a,b   Bujko, Mateusz ^a   Plisiecka Halasa, Joanna ^a   Madry, Radoslaw ^c   Osuch, Beata ^d   Markowska, Janina ^c   Bidzinski, Mariusz ^a   Kupryjanczyk, Jolanta ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b INSTITUTE OF GENETICS AND ANIMAL BREEDING   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d Brodnowski Hospital Warsaw   (Poland)

Author keywords

BRCA1 germline mutations; Loss of heterozygosity; Methylation; PIK3CA; TP53

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE AMPLIFICATION; GENE LOCUS; GENE LOSS; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HETERODUPLEX ANALYSIS; HETEROZYGOSITY LOSS; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CARCINOMA; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; DNA METHYLATION; FEMALE; GENE AMPLIFICATION; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84860251742     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.12.005     Document Type: Article

References (41)

1. Weberpals J.I., Clark-Knowles K.V., Vanderhyden B.C. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 2008, 26:3259-3267.
2. Prat J., Ribe A., Gallardo A. Hereditary ovarian cancer. Hum Pathol 2005, 36:861-870.
3. Ramus S.J., Gayther S.A. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009, 3:138-150.
4. Walsh C.S., Ogawa S., Scoles D.R., et al. Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res 2008, 14:7645-7651.
5. Lakhani S.R., Manek S., Penault-Llorca F., et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004, 10:2473-2481.
6. Werness B.A., Ramus S.J., Whittemore A.S., et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 2000, 31:1420-1424.
7. Wang C., Horiuchi A., Imai T., et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004, 202:215-223.
8. Wilson C.A., Ramos L., Villasenor M.R., et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999, 21:236-240.
9. Zheng W., Luo F., Lu J.J., et al. Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol 2000, 76:294-300.
10. Thrall M., Gallion H.H., Kryscio R., et al. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2006, 16(suppl 1):166-171.
11. Brozek I., Ochman K., Debniak J., et al. Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers. J Appl Genet 2009, 50:379-384.
12. Clark-Knowles K.V., Garson K., Jonkers J., et al. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 2007, 313:133-145.
13. Aghmesheh M., Nesland J.M., Kaern J., et al. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. Gynecol Oncol 2004, 95:430-436.
14. Buller R.E., Lallas T.A., Shahin M.S., et al. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res 2001, 7:831-838.
15. Rhei E., Bogomolniy F., Federici M.G., et al. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 1998, 58:3193-3196.
16. Tong D., Kucera E., Schuster E., et al. Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors. Int J Cancer 2000, 88:319-322.
17. Villeneuve J.B., Silverman M.B., Alderete B., et al. Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer. Genes Chromosomes Cancer 1999, 25:65-69.
18. Tavassoli F.A., Devilee P. Pathology and genetics of tumours of the breast and female genital organs 2003, IARC Press, Lyon.
19. Barber H.R., Sommers S.C., Synder R., et al. Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer. Am J Obstet Gynecol 1975, 121:795-807.
20. Creasman W. Announcement, FIGO stages 1988, revisions. Gynecol Oncol 1989, 35:125-127.
21. Dansonka-Mieszkowska A., Ludwig A.H., Kraszewska E., et al. Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Genet 2006, 70:594-604.
22. Kolasa I.K., Rembiszewska A., Felisiak A., et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 2009, 8:21-26.
23. Kolasa I.K., Rembiszewska A., Janiec-Jankowska A., et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol 2006, 103:692-697.
24. Esteller M., Silva J.M., Dominguez G., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92:564-569.
25. Eads C.A., Lord R.V., Wickramasinghe K., et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001, 61:3410-3418.
26. Press J.Z., De Luca A., Boyd N., et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008, 8:17.
27. Majdak E.J., Debniak J., Milczek T., et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005, 104:1004-1012.
28. Menkiszak J., Gronwald J., Gorski B., et al. Hereditary ovarian cancer in Poland. Int J Cancer 2003, 106:942-945.
29. Gorski B., Byrski T., Huzarski T., et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2000, 66:1963-1968.
30. Janiszewska H., Haus O., Lauda-Swieciak A., et al. Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland. Clin Genet 2003, 64:502-508.
31. Bowtell D.D. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010, 10:803-808.
32. Shih I.E.M., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164:1511-1518.
33. Russell P.A., Pharoah P.D., De Foy K., et al. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 2000, 87:317-321.
34. Geisler J.P., Hatterman-Zogg M.A., Rathe J.A., et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002, 94:61-67.
35. Jeng Y.M., Cai-Ng S., Li A., et al. Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation. Oncogene 2007, 26:6160-6166.
36. Werness B.A., Parvatiyar P., Ramus S.J., et al. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cancer Inst 2000, 92:1088-1091.
37. Baldwin R.L., Nemeth E., Tran H., et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000, 60:5329-5333.
38. Ramus S.J., Bobrow L.G., Pharoah P.D., et al. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 1999, 25:91-96.
39. Zweemer R.P., Shaw P.A., Verheijen R.M., et al. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol 1999, 52:372-375.
40. Jazaeri A.A., Yee C.J., Sotiriou C., et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002, 94:990-1000.
41. Ramus S.J., Pharoah P.D., Harrington P., et al. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 2003, 63:417-423.